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Objectives: The aim of this study was to analyze the clinical efficacy and cytomorphologic 
changes of colon mucosa following the treatment of patients suffering from irritable bowel 
syndrome (IBS) with mesalazine (5-aminosalicylic acid [5-ASA]).
Methods: In this controlled, randomized, blind clinical trial, a total of 360 patients with varying 
subtypes of IBS were randomly treated with 500 mg of mesalazine qid or by standard therapy 
without mesalazine for a period of 28 days. Pre- and post-treatment pain intensity, pain   duration, 
meteorism, stool abnormalities and endoscopic parameters were monitored, and biopsies or 
brush biopsies were examined histologically.
Results: Treatment of IBS patients with mesalazine significantly reduced intensity and duration 
of pain in all subtypes of IBS, except for duration of pain in the subtype “undifferentiated”, where 
the difference was not significant. In addition, in patients with diarrhea type and undifferentiated 
type of IBS, mesalazine also significantly reduced the abnormal stool pattern. In comparison 
to the control group, administration of mesalazine reduced the incidence of endoscopic and 
cytomorphologic changes of the bowel mucosa, including changes in colon mucus, mucus 
production, cytologic or histologic parameters, epithelial cell degeneration, appearance of 
leukocytes and macrophages and cell infiltrations.
Conclusion: Mesalazine was effective in reducing several symptoms characteristic of IBS. 
It significantly reduced pain intensity and duration and improved cytohistologic parameters of 
the bowel mucosa.
Keywords: 5-amino salicylic acid, 5-ASA, abdominal pain, irritable bowel syndrome, IBS, 
meteorism, stool abnormalities
Introduction
Irritable bowel syndrome (IBS) is the most common functional bowel disorder. It is 
characterized by abdominal pain, bloating and disturbed defecation. The first report 
on IBS dates to 1818.1
Morbidity varies from 30% to 50% in Europe, the United States and Japan, and 
amounts to more than 60% in post-Soviet countries.2–4 In spite of numerous attempts 
to discover the triggers, etiology and pathogenesis, the pathophysiology of the disease 
is still unclear. The influence of psychogenic disorders, visceral hypersensitivity and 
abnormal bowel motility in genesis of IBS is broadly acknowledged.3,5,6
Bowel infections, bacterial overgrowth syndrome, antibiotics, stress and 
unfavorable dietary habits can precede visceral hypersensitivity and lead to a clinical 
manifestation of IBS. Although there is no specific morphologic correlate of IBS, Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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these predictors can affect the colon microbiota and the local 
immune system, decrease the protective properties of the 
bowel mucosa, impair mucus production, and may be caused 
by only minimal alterations on the   cellular level.
Histomorphologic analysis of biopsies in IBS is often 
negative with respect to pathological findings. Occasionally 
minimal violations or initial signs of edema of the colon 
mucosa, an increase in diameter of capillaries, constriction 
or dilatation of crypts, abundance of mucus in crypts, slight 
increase in number of goblet cells, dystrophy of solitary 
epithelial cells, increased number of fibroblasts within the 
stroma and cellular infiltrations are detectable. The detection 
of minor lesions is often accompanied by a decrease of 
  proliferation and enhanced apoptosis of colonocytes.3,7 
Progression of the disease leads to more pronounced 
  morphological changes of the colon mucosa epithelium: 
reduced frequency of serotonin-producing cells and mast cells 
and increased frequency of secondary cells and increasing 
number of cellular infiltrations by eosinophils, neutrophils, 
lymphocytes, plasmocytes and fibroblasts of stroma.7 These 
morphological criteria are signs of inflammatory processes 
and activation of immune mechanisms, and could explain 
why IBS often is refractory to standard types of treatment. 
Elimination of inflammatory processes in colon mucosa 
could be one of the most promising targets of therapy for 
IBS patients.
Progress in the development of diagnostic tools, such 
as positron emission tomography and functional magnetic 
resonance imaging of the brain, have contributed considerably 
to understanding of the brain-gut interaction,8,9 indicating a 
possible psychophysiologic component,10,11 in addition to 
the hypothesis that altered motility is the primary underlying 
pathophysiologic basis of IBS. Most recently, evidence 
has accumulated suggesting that immune activation affects 
intestinal function and sensory perception as part of symptom 
generation in patients with IBS.12,13 However, these results 
are controversial, because contradictory results have been 
presented by several authors.14,15
The first attempt to classify IBS was published by 
Manning et al16 followed by Kruis et al six years later.17 
Several consensus conferences subsequently tried to develop 
diagnostic criteria for the classification and safe diagnosis 
of gastrointestinal disorders (“Rome criteria”18–20 Table 1, 
Table 2). The validity of the Rome criteria has been reported 
in several studies.21,22
Due to the uncertainty of the pathophysiologic basis 
of IBS, numerous studies attempted to find a rationale for 
the reliable pharmacological treatment of this disease. The 
failure of corticosteroids stimulated the targeting of the 
immune system, eg, by mast cell stabilizers.14 Moreover, 
the therapeutic potential of aminosalicylates, well known 
for their benefits in chronic inflammatory bowel diseases, 
has attracted renewed interest as a potential cure for IBS.12 
To better study both relief and outcome in IBS, the Rome 
foundation initiated a complex systematic review and meta-
analysis of the psychometric and performance characteristics 
of primary endpoints used in large multicenter therapeutic 
trials for irritable bowel syndrome using pharmacological 
approaches.23
Patients and methods
study sites and design
The study was performed in three centers in the Ukraine 
between 2006 and 2009, as a controlled post-marketing 
observational study with 360 patients diagnosed with an 
irritable bowel syndrome and sub-grouped in accordance 
with the Rome III criteria.
As a primary outcome parameter, we selected pain 
intensity. Secondary parameters were pain duration, mete-
orism, stool abnormalities and histocytologic parameters.
Table  1  Diagnostic  criteria  according  to  the  latest  issue  of 
“rome iii”2
recurrent abdominal pain or discomfort* at least 3 days/month in the 
last 3 months associated with two or more of the following:
1. improvement with defecation 
2. Onset associated with a change in frequency of stool 
3. Onset associated with a change in form (appearance) of stool
Criterion fulfilled for the last 3 months with symptom onset at least  
6 months prior to diagnosis.
Notes: *“Discomfort” means an uncomfortable sensation not described as pain.   
in pathophysiology research and clinical trials, a pain/discomfort frequency of at least 
2 days a week during screening evaluation is recommended for subject eligibility.
Table 2 Subtyping of IBS by predominant stool pattern modified 
according to Longstreth2
1.   iBs with constipation (iBs-C) – hard or lumpy stoolsa $25% and loose 
(mushy) or watery stoolsb ,25% of bowel movementsc.
2.   iBs with diarrhea (iBs-D) – loose (mushy) or watery stoolsb $25% 
and hard or lumpy stoola ,25% of bowel movementsc.
3.   Mixed iBs (iBs-M) – hard or lumpy stoolsa $25% and loose (mushy) 
or watery stoolsb $25% of bowel movementsc.
4.   Undifferentiated (IBS-U) – insufficient abnormality of stool consistency 
to meet criteria for iBs-C, -D, or -Mc.
Notes: aBristol Stool Form Scale 1–2 (separate hard lumps like nuts [difficult to 
pass] or sausage-shaped but lumpy);  bBristol Stool Form Scale 6–7 (fluffy pieces 
with ragged edges, a mushy stool or watery, no solid pieces, entirely liquid); cin the 
absence of use of antidiarrheals or laxatives.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Ethics
The study was approved by the ethics committees of the 
National Medical University of Donetsk and the Gastro-
enterological Center of Poltava Hospital Clinic, Poltava, 
Ukraine, according to the legal requirements of the State 
of Ukraine.
Diagnosis of iBs
Diagnosis of IBS was established according to Rome III 
criteria (2006) and included: Recurrent abdominal pain or 
discomfort for $3 days per month during the last 3 months, 
associated with $2 of the following:
•	 Improvement of defecation
•	 Changes in stool frequency
•	 Changes in stool consistency
Diagnostic criteria needed to have been fulfilled for 
the last 3 months with symptom onset $6 months prior to 
diagnosis.
Patients with IBS were divided into subgroups depending 
on stool pattern according to the Bristol Stool Form Scale.
Occurrences of infections were assessed by anamnesis 
from the beginning throughout the duration of IBS. Post 
infectious IBS was considered as a special form of IBS: we 
did not exclude this group of patients from the study. Absence 
of any bowel infection was confirmed by microbiological 
stool examination before diagnosis of IBS and inclusion 
into the study.
Any organic pathology was excluded first of all (in com-
pliance with Rome III criteria) by exclusion of the specific 
alarm symptoms such as first symptoms at age $50 years, 
loss of weight, blood in stool, fever, cancer anamnesis in 
relatives.
Besides histomorphologic analysis of the biopsies we 
proved absence of any organic pathology or infection. 
  Evidence of inflammation (hyperemia, edema, granulations) 
were considered as a mild inflammatory process in IBS.
Genetic predisposition to IBS was not found in inves-
tigated patients. Different dietary abnormalities associated 
with specific IBS types (constipation or diarrhea) were found 
in all patients. However, patients with a strict diet regimen 
(eg, vegetarians) were excluded from the study.
statistical analysis
Statistical analysis started from verification of results 
of   normal dispensation by W-test (Shapiro–Wilk) and 
  Chi-square test. Descriptive statistics with calculation 
of mean values, standard deviations and median were 
  performed. Significance of differences of mean values was 
determined by Student’s t-test.
Patients
A total of 240 patients from an industrial region with 
unfavorable ecology and 120 patients from an agricultural 
region without this negative impact were recruited. The 
gender distribution was 105 (29.2%) men and 255 (70.8%) 
women. Average age was 43.2 ± 3.3 years. Diagnosis of IBS 
and sub-grouping was based on clinical symptoms according 
to Rome III criteria, 2006,2 as described in Table 2.
Patients were randomized in 2 groups. Each third patient 
with any type of IBS was assigned to the treatment group and 
obtained mesalazine (Salofalk®) 2.0 g per day for 28 days. Thus 
120 IBS patients received 500 mg tablets qid after a meal. The 
remaining 240 IBS patients were assigned to the control group 
and received a standard treatment without mesalazine.
Standard treatment according to Rome III was   followed 
during the investigation. Patients with diarrhea received 
loperamide (2–4 mg when necessary), patients with 
constipation received psyllium husks (Plantago ovata, 
  Mucofalk®, 3.25 g bid with meals) or lactulose syrup 
(15–20 mL bid); patients with abdominal pain syndrome 
received mebeverine 400 mg per day. Some patients with 
severe meteorism received simethicon limited to 3–5 days.
Before and after treatment, patients characterized their 
pain intensity by a visual-analog scale (0 = no pain to 
10 = worst imaginable pain). Duration of pain, incidence 
of meteorism and stool abnormalities were queried and 
documented by the physicians.
Endoscopy was done for all patients before and after 
treatment. Colonoscopy was done for 200 patients and 
  sigmoidoscopy for 160 patients. During endoscopy the color 
and intensity of hyperemia, evidence of edema and granulations 
scattering reflected light in colon mucosa were investigated. 
Characteristics of vascular pattern, presence of mucus on the 
colon wall and haustrations were also analyzed.
Before and after 1 month of treatment, endoscopy was 
carried out on each patient by the same physician.
In addition to visual examination during endoscopy, 
biopsies of the colon mucosa were taken in 90 patients, but 
in 150 patients brush-biopsies were preferred.
Brush-biopsies were performed by an abrasive brush 
brought in contact with visually abnormal or suspicious 
areas of the colon mucosa. Thereafter the material was 
transferred to a microscope slide and air dried. The samples 
were then stained according to the Pappenheim method Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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  (May-Grünwald-Giemsa solution, ie, methylene blue plus 
eosin in a methanolic solution for 3 minutes). In brush-
biopsies the number and type of epithelial cells, leukocytes, 
erythrocytes, lymphocytes and bacteria were analyzed.
For histologic analysis, biopsies of the colon mucosa were 
chemically fixed in a 5% formaline solution, subjected to a 
conventional paraffin embedding procedure and subsequent 
staining of the 2–3 µm sections by hematoxyline-eosin-alcian 
blue at pH 1.0 and 2.5 for the determination of sulfated and 
non-sulfated glucosaminoglycans and glycoproteins, and 
for goblet cells and colon mucus. To characterize the mucus 
production, the Periodic Acid Schiff reaction (PAS-reaction) 
was used.
Histological sections were examined with respect to the 
number and maturity of goblet cells as well as the amount 
and maturity of the mucus. Furthermore, the intensity of cell 
infiltrations and their character was determined.
Results
Patients’ age and duration of iBs symptoms
A total of 291 (80.8%) patients came down with IBS 
before the age of 45 years. In 7.5% of all patients IBS was 
diagnosed between 56 and 65 years of age (no significant 
difference between males and females). The incidence of 
IBS was highest in males at the age between 26 to 35 years 
(n = 39, 37.1% [P , 0.01 as compared with females, n = 60, 
23.5% and as compared with the total, n = 99, 27.5%]). The 
highest incidence of IBS in women was in the age group of 
15–25 years. There was no significant difference in the age 
distribution of women compared with the intention-to-treat 
population (Figure 1).
At first diagnosis, duration of IBS varied from 6 months 
to 25 years. Most females had symptoms of IBS for a period 
of 5–10 years (79.4% of this group, n = 81), most males 
suffered from IBS for a period of 1–3 years (35.9% of this 
group, n = 42) (Figure 2).
At first diagnosis, patients were allocated to four 
categories of IBS according to the Rome III criteria: IBS 
with constipation (IBS-C), IBS with diarrhea (IBS-D), IBS 
mixed (IBS-M) and IBS undifferentiated (IBS-U) (Figure 3). 
Overall, IBS-C was the most frequent category (43.3% or 
156 of 360), which was most infrequent in the age group of 
36–45 (26.5%), followed by the IBS-D category (35.0% or 
126 of 360). The IBS-D category predominated in age groups 
from 18–45 years, with lower incidence at an age above 
46 years. The mixed type IBS-M was diagnosed in 57 patients 
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Figure 1 Gender-dependent age distribution of patients at onset of iBs symptoms. 
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(15.8%) and prevailed in the two age groups 18–25 and 
36–45 years. IBS-U was diagnosed in a total of 5.8% of 
patients, the percentage increasing with age of patients, ie, it 
was most frequently diagnosed in the older patients.
We also determined the incidence of predisposing factors 
for IBS. The factors occurring most frequently were stress 
(40.8%) and chronic urogenital disorders (35.6%) followed 
by bowel infections (27.5%), low physical activity (25.8%) 
and obesity (20.0%) (Figure 4).
Efficacy
Pain intensity
Intensity of pain before treatment and after 28 days’ therapy 
with either mesalazine or conventional therapy without 
mesalazine was judged by the patients on a visual analog 
scale (0–10). In all IBS categories, the pain intensity was 
significantly lower in the mesalazine group (1.4 ± 0.4, n = 120 
of 360 patients) compared with the control group (3.8 ± 0.6, 
n = 240 of 360 patients: see Figure 5). The highest pain score 
was determined in the IBS-U group (8.7 ± 0.9), which was 
significantly higher compared to the other pain scores before 
treatment, except for the pain score in IBS-M. Mesalazine 
was less effective in IBS-M and IBS-U, albeit significantly 
better compared with controls within each   particular IBS-
category. The difference between the pain score in the 
mesalazine group with IBS-U is significant, compared with 
all other groups (P , 0.01).
Pain duration
Pain duration was queried and recorded by the   physicians. 
The most unfavorable situation was found in the IBS-U 
group, where the mean pain duration was highest 
(11.0 ± 1.2 hours per day). This level of pain duration at 
baseline was significantly higher compared with all other 
baseline values. Moreover, in this group, there was no 
difference between the treatment with mesalazine and the 
control group. In all other IBS categories mesalazine treat-
ment reduced pain duration significantly (Figure 6). The 
most pronounced reduction in pain duration occurred in the 
IBS-C and IBS-D group.
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Figure 2 Gender-dependent distribution of duration of IBS symptoms at first diagnosis. 
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incidence of stool abnormalities
At baseline, stool abnormalities were present in all patients. 
By mesalazine treatment, the number of patients with stool 
abnormalities was significantly reduced in the IBS-D and 
IBS-U group only. In each case, the treatment of IBS by stan-
dard or mesalazine therapy provided a significant reduction 
in the percentage of patients with stool abnormalities 
(Figure 7).
incidence of meteorism
At baseline most patients suffered from meteorism.   Standard 
therapy and therapy including mesalazine reduced the 
number of patients with meteorism significantly in all IBS 
categories. The difference between standard therapy and 
mesalazine therapy was significant only in the IBS-D and 
the IBS-M group (Figure 8).
Cytomorphologic findings
Results of a cytomorphologic analysis of brush biopsies in 
patients with different categories of IBS at baseline, which 
was performed to assess possible differences between IBS 
categories, are presented in Figure 9. Figure 9 includes only 
cytomorphologic parameters with significant   differences 
to the basic population. Significant differences were seen 
between the basic population (n = 150) and the IBS-C 
group (significantly less “epithelial cells with degeneration”, 
  column 3), the IBS-D group (significantly more   “pavement 
cells without changes”, column 1, and significantly lower 
incidence of “mixed bacterial flora”, column 5), the IBS-M 
group (significantly more “columnar epithelial cells”, 
  column 2), and the IBS-U group (significantly higher 
incidence of “nuclear polymorphism in epithelial cells”, 
column 4, and significantly higher incidence of “mixed 
bacterial flora”, column 5).
Incidence of cytomorphologic parameters following treat-
ment with mesalazine compared with the control group con-
sidered the parameters “colon mucus changes”, “  cytological 
or histological changes”, “epithelial cell degeneration”, “sin-
gular leukocytes or macrophages”, “mild cell infiltrations” 
and “mucus production” (Figure 10, pairs of columns 1–6). 
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The parameters “epithelial cell degeneration” (column 3) and 
“mucus production” (column 6) showed no significant dif-
ference between mesalazine treatment and controls. With all 
other parameters the difference between treatment and con-
trols was significant (P , 0.05, columns 1 and 4; P , 0.01, 
columns 2 and 5), ie, reduction of colon mucus changes, 
reduction of cytologic or histologic changes, reduction of 
singular leukocytes or macrophages and less cell infiltrations 
as a result of mesalazine treatment.
Cell infiltrations were found in 2 (6.7%) patients, who 
received mesalazine in contrast to 20 (33.3%) patients in the 
control group (P , 0.01). Abnormal mucus production was 
seen in 8 (26.7%) patients in the mesalazine group and 27 
(45.0%) patients in the control group (Figure 10).
Most patients with cytomorphologic changes after 
treatment were between 38 and 47 years old, suffered from 
IBS for more than 3 years, and had several predisposing 
factors and endoscopic changes before treatment. 12 of 34 
(35.3%) patients from this group suffered from constipation 
type IBS.
For morphological evaluation of peculiarities of the 
colon mucosa, histological analyses were performed in 
90 IBS patients who had signs of inflammatory reactions 
during endoscopic examination. The histologic pattern 
and changes of the intensity of the colon mucosa showed 
considerable variations. Abnormal mucus production and 
moderate inflammatory changes prevailed in the IBS patients 
examined. A number of 39 (43.3%) patients had a regular 
columnar epithelium, single goblet cells and normal numbers 
of endocrinocytes (Figure 11).
A flattening of the superficial epithelium of 10–15 µm 
was found in 30 (33.3%) patients, and foci of desquamation 
in 18 (20.0%) IBS patients (Figure 12).
An abundance of crypts with a diameter of 80 µm was 
observed. Goblet cells in crypts predominated in 50 (55.6%) 
IBS patients at the mucus production phase, which could 
be evidence of mucus hyperproduction (Figure 13). In 41 
(45.6%) patients, the structure of goblet cells appeared 
  normal. The composition of mucus had changed in 52 
(57.8%) IBS patients. In 32 (35.6%) patients, the balance 
between sulfated and non-sulfated glucosaminoglycans 
and glycoproteins was altered according to the alcian blue 
staining (data not shown). The level of sulfated glycoproteins 
had increased. In 20 (22.2%) IBS patients a minor decrease 
in PAS-reaction of mucus in goblet cells was observed (data 
not shown).
Edemata of the intercryptal space were present in 35 
(38.9%) patients (Figure 14B). At all investigated biopsies 
mild cell infiltrations could be seen. The infiltrates consisted 
of plasmocytes (40%–50%) and lymphocytes (30%–40%): 
evidence of eosinophils and fibroblasts was found in the basal 
part of the mucosa (37 patients, 41.1%; Figure 14A, B).
In the submucous layer abnormal vascular patterns were 
present in 64 (71.1%) IBS patients. Abundant venous micro-
capillaries and sometimes venous stasis phenomena were 
present. Occasionally, foci of lymphoid and plasmocytic 
infiltrations and lymphoid follicles were detected in the 
submucosal layer (Figure 15A, B).
safety analysis
The frequency of adverse events (AEs), clinically relevant 
changes in laboratory analysis and vital signs were assessed. 
A total of 44 AEs were reported in 42 (11.7%) patients. 
Among them 13 patients (10.8%) obtained mesalazine and 
standard treatment and 29 patients (12.1%) received standard 
treatment only. No drug-related AEs were revealed in either 
group. The AEs most frequently reported in both groups 
of patients were headache, nasopharyngitis, and flu-like 
infection. There was no significant difference in frequency of 
these AEs in the two groups. All patients who reported AEs, 
experienced AEs of mild intensity. There was no evidence 
for serious AEs in IBS patients during the study.
Discussion
The pathophysiology of IBS has long been discussed and 
is still to be elucidated. The Rome Foundation has spent 
many years collecting data from experts and updating our 
knowledge about this disease,2,23 a process that continuously 
results in improvement in diagnosis and characterization 
of different aspects of IBS and thus the optimization of 
  individual patient-oriented therapies.
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Figure 13 Goblet cells (1), crypts (2) in colon mucosa in iBs patient (hematoxylin-
eosin staining, bar = 100 µm). 
Abbreviation: iBs, irritable Bowel syndrome.
Figure 11 Colon mucosa of iBs patient (1 – columnar epithelium, 2 – goblet cells, 
3 – endocrinocytes, hematoxylin-eosin staining, bar = 100 µm). 
Abbreviation: iBs, irritable Bowel syndrome.
Figure 12 Flattening of superficial epithelium (1) in colon mucosa in iBs patient 
(hematoxylin-eosin staining, bar = 200 µm). 
Abbreviation: iBs, irritable Bowel syndrome.
The pharmacological treatment of IBS is still   controversial, 
due to the lack of knowledge about causal   interdependencies. 
A plethora of drugs has been suggested for treatment of 
diarrhea, constipation and abdominal pain in IBS, but most 
treatments help only in a selected cohort of patients, and a 
significant and convincing success is still missing.2,12 That is 
why Barbara et al recently concentrated on the importance 
of immune activation in the context of IBS.12 Several studies 
seem to corroborate the hypothesis that immune activation 
may contribute to symptom generation in IBS patients.24–32 
Consequently the Barbara group initiated a “proof of 
concept” study to investigate the efficacy of mesalazine, a 
candidate well known and established as a remedy for inflam-
matory bowel diseases like ulcerative colitis and Crohn’s 
disease.33 They found that mesalazine markedly reduced 
Figure  14  Cell  infiltrations  A)  and  edema  B)  in  colon  mucosa  in  iBs  patient   
(1 – plasmocytes, 2 – lymphocytes, 3 – eosinophils, 4 – fibroblasts, hematoxylin-
eosin staining). Bars = 50 µm. 
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At the same time, mucosal micro-inflammation in IBS can 
be a result of impact on visceral innervation, and an imbal-
ance of serine/histamine. Amine precursor uptake decarboxy-
lase (APUD) peptides are not related to   infections. Hence, in 
our opinion, mesalazine is better suited for basic treatment of 
IBS considering the main pathogenetic mechanisms.
Conclusion
Mesalazine is effective in reducing abdominal pain in 
patients with different types of IBS. The duration of pain 
is also reduced significantly by treatment with   mesalazine. 
  Moreover, meteorism and abnormal stool pattern are 
improved significantly in some subtypes of IBS.
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